Conference Coverage

Cannabis for pain linked to slight risk for arrhythmia


 

FROM ESC CONGRESS 2022

Cancer, musculoskeletal, and neurologic pain

For this analysis, the researchers identified 1.8 million patients in Denmark who were diagnosed with chronic pain between 2018 and 2021.

Of those, around 5,000 patients had claimed at least one prescription of medicinal cannabis (dronabinol 29%, cannabinoids 46%, or cannabidiol 25%).

The patients had a median age of 60 years, and 63% were women.

The cannabis users had been prescribed this therapy for musculoskeletal (35%), cancer (18%), neurological (14%), or other (33%) pain, Dr. Nouhravesh said.

The researchers and Dr. Olshansky have no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Meta-analysis points to safety of acetylcholine coronary testing
MDedge Family Medicine
Cardiologists concerned for patient safety after abortion ruling
MDedge Family Medicine
‘Stunning variation’ in CV test, procedure costs revealed at top U.S. hospitals
MDedge Family Medicine
‘Staggering’ CVD rise projected in U.S., especially in minorities
MDedge Family Medicine
Using wearable devices to detect AFib ‘cost effective’
MDedge Family Medicine
‘Obesity paradox’ in AFib challenged as mortality climbs with BMI
MDedge Family Medicine
AHA statement outlines symptoms of common heart diseases
MDedge Family Medicine
Barcelona beckons for first hybrid ESC Congress
MDedge Family Medicine
Low-dose edoxaban curbs stroke risk in elderly with AF, despite frailty
MDedge Family Medicine
Early menopause linked with increased risk of heart problems
MDedge Family Medicine